{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-100231","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2024-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.105614+00:00","generated_at":"2026-05-29T22:49:34.907173+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Emmaus Life Sciences Q3 net revenue up 9% to $5.5M; net income $1.8M vs $0.07M YoY","bullets":["Net revenues $5.5M (+9% YoY) driven by Middle East sales; U.S. sales fell due to generic L-Glutamine competition.","Q3 income from operations $0.8M (vs $0.02M YoY); net income $1.8M ($0.03 EPS) vs $0.07M.","Nine-month net loss $4.7M ($0.07 per share) vs $4.9M loss in prior year; revenue down 41% due to inventory shortages.","Cash at Sept 30, 2024: $1.3M, down from $2.5M at Dec 31, 2023.","CEO expects full-year results materially lower than 2023; generic competition may affect future Endari sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-100231","json":"https://secwatch.observer/filing/0001213900-24-100231.json","markdown":"https://secwatch.observer/filing/0001213900-24-100231.md","text":"https://secwatch.observer/filing/0001213900-24-100231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390024100231/0001213900-24-100231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390024100231/ea0221824-8k_emma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:49:34.907173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}